Novel DNA Bis-Intercalator XR5944 as a Potent Anticancer Drug-Design and Mechanism of Action.
DNA
MLN944
NMR
XR5944
anticancer drug
bis-intercalator
major groove binder
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
07 Jul 2021
07 Jul 2021
Historique:
received:
28
04
2021
revised:
18
06
2021
accepted:
29
06
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
11
9
2021
Statut:
epublish
Résumé
This review is dedicated to Professor William A. Denny's discovery of XR5944 (also known as MLN944). XR5944 is a DNA-targeted agent with exceptionally potent antitumor activity and a novel DNA binding mode, bis-intercalation and major groove binding, as well as a novel mechanism of action, transcription inhibition. This novel anticancer compound represents a remarkable accomplishment resulting from two decades of drug discovery by Professor Denny and coworkers. Here, we review our work on the structural study of the DNA binding mode of XR5944 and mechanistic study of XR5944 action.
Identifiants
pubmed: 34299405
pii: molecules26144132
doi: 10.3390/molecules26144132
pmc: PMC8304338
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Intercalating Agents
0
Phenazines
0
XR5944
0
DNA
9007-49-2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM125620
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA240346
Pays : United States
Organisme : Foundation for the National Institutes of Health
ID : R01CA177585
Organisme : Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)-Projektnummer
ID : 427347592
Organisme : NCI NIH HHS
ID : R01 CA177585
Pays : United States
Organisme : Foundation for the National Institutes of Health
ID : P30CA023168
Organisme : Foundation for the National Institutes of Health
ID : U01CA240346
Organisme : NCI NIH HHS
ID : P30 CA023168
Pays : United States
Références
Bioorg Med Chem Lett. 2002 Feb 11;12(3):415-8
pubmed: 11814810
J Med Chem. 1987 May;30(5):843-51
pubmed: 3572972
Biochem Pharmacol. 2018 Sep;155:336-345
pubmed: 30040927
J Biol Chem. 2004 Oct 29;279(44):46096-103
pubmed: 15317822
Breast Cancer. 1995 Oct 31;2(2):79-89
pubmed: 11091537
Br J Cancer. 2005 Feb 28;92(4):722-8
pubmed: 15700035
J Steroid Biochem Mol Biol. 2011 Apr;124(3-5):121-7
pubmed: 21333738
Mol Cancer Ther. 2004 Jan;3(1):47-58
pubmed: 14749475
Oncologist. 2018 May;23(5):528-539
pubmed: 29352052
J Steroid Biochem Mol Biol. 2010 Jun;120(4-5):172-9
pubmed: 20403436
Mol Cancer Ther. 2007 Jan;6(1):213-9
pubmed: 17218634
Nucleic Acids Res. 2000 Nov 1;28(21):4244-53
pubmed: 11058124
Mol Cancer Ther. 2005 Aug;4(8):1260-7
pubmed: 16093442
Beilstein J Org Chem. 2018 May 16;14:1051-1086
pubmed: 29977379
Anticancer Drugs. 2005 Oct;16(9):945-51
pubmed: 16162971
Eur J Cancer. 1996 Apr;32A(4):708-14
pubmed: 8695277
Mol Endocrinol. 2005 Apr;19(4):833-42
pubmed: 15695368
Mol Cancer Ther. 2004 Dec;3(12):1631-7
pubmed: 15634657
J Med Chem. 2001 Apr 26;44(9):1407-15
pubmed: 11311063
Nucleic Acids Res. 2014 May;42(9):6012-24
pubmed: 24711371
Anticancer Drugs. 2001 Apr;12(4):359-67
pubmed: 11335793
J Med Chem. 1987 Apr;30(4):664-9
pubmed: 3560161
Exp Hematol Oncol. 2018 Sep 19;7:24
pubmed: 30250760
Br J Cancer. 2007 Oct 8;97(7):844-50
pubmed: 17848959
Annu Rev Biochem. 2010;79:233-69
pubmed: 20334529
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Drug Discov Today Dis Mech. 2012;9(1-2):e11-e17
pubmed: 23539064
Pharmacol Rev. 1998 Jun;50(2):151-96
pubmed: 9647865
J Med Chem. 2000 Apr 6;43(7):1350-8
pubmed: 10753472
Anticancer Drug Des. 1999 Jun;14(3):281-9
pubmed: 10500503
J Med Chem. 1984 Nov;27(11):1481-5
pubmed: 6492078
J Med Chem. 1988 Apr;31(4):707-12
pubmed: 3351846
Biopolymers. 2014 Nov;101(11):1099-113
pubmed: 24898663
Cancer Chemother Pharmacol. 2017 Jul;80(1):1-14
pubmed: 28528358
J Med Chem. 1999 Feb 25;42(4):536-40
pubmed: 10052960